Antidepressant pretreatment for the prevention of interferon alfa-associated depression: A systematic review and meta-analysis

Psychosomatics

Volumn 55, Issue 3, 2014, Pages 221-234

  Sarkar, Susanne ^a   Schaefer, Martin ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKEN ESSEN MITTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; ANTIVIRUS AGENT;

ARTICLE; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DRUG INDUCED DISEASE; HEPATITIS C; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; META ANALYSIS; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; CHEMICALLY INDUCED; CHEMOPROPHYLAXIS; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; HEPATITIS C, CHRONIC; MELANOMA;

ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; CHEMOPREVENTION; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MELANOMA; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84899498570     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2013.06.015     Document Type: Article

References (44)

1. Schaefer M., Engelbrecht M.A., Gut O., et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:731-746.
2. Hauschild A., Kahler K.C., Schafer M., Fluck M. Interdisciplinary management recommendations for toxicity associated with interferon-alfa therapy. J Dtsch Dermatol Ges 2008, 6:829-838.
3. Heinze S., Egberts F., Rotzer S., et al. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial. J Immunother 2010, 33(1):106-114.
4. Trask P.C., Paterson A.G., Esper P., Pau J., Redman B. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psychooncology 2004, 13:526-536.
5. Reichenberg A., Gorman J.M., Dieterich D.T. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 2005, 19(3 Suppl):S174-S178.
6. Schaefer M., Schwaiger M., Garkisch A.S., et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005, 42:793-798.
7. Schafer A., Wittchen H.U., Seufert J., Kraus M.R. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C-a critical review. Int J Methods Psychiatr Res 2007, 16:186-201.
8. Sockalingam S., Links P.S., Abbey S.E. Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. J Viral Hepat 2011, 18:153-160.
9. Capuron L., Gumnick J.F., Musselman D.L., et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
10. Capuron L., Miller A.H. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011, 130:226-238.
11. Kraus M.R., Schafer A., Schottker K., et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008, 57:531-536.
12. Leutscher P.D., Lagging M., Buhl M.R., et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010, 52:430-435.
13. Schaefer M., Sarkar R., Knop V., et al. Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C Virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med 2012, 157:94-103.
14. Ziefle S., Egberts F., Heinze S., et al. Health-related quality of life before and during adjuvant interferon-alpha treatment for patients with malignant melanoma (DeCOG-trial). J Immunother 2011, 34:403-408.
15. Mann J.J. The medical management of depression. N Engl J Med 2005, 353:1819-1834.
16. Knott A., Dieperink E., Willenbring M.L., et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006, 101(10):2254-2262.
17. Schaefer M., Capuron L., Friebe A., et al. Hepatitis C infection, antiviral treatment and Mental Health: a European Expert Consensus Statement. J Hepatol 2012, 57(6):1379-1390.
18. Diagnostic and Statistical Manual of Mental Disorders-DSM-IV-TR (4th edition, Text Revision) 1994, APA-American Psychiatric Association, American Psychiatric Association, Washington, D.C. DSM-IV: 4th ed.
19. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
20. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967, 6:278-296.
21. Higgins J.P.T., Thompsen S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. Br Med J 2003, 327:557-560.
22. Kraus M.R., Schäfer A., Faller H., Csef H., Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002, 16(6):1091-1099.
23. Gleason O.C., Fucci J.C., Yates W.R., Philipsen M.A. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C-a pilot study. Dig Dis Sci 2007, 52(10):2557-2563.
24. Hosoda S., Takimura H., Shibayama M., et al. Antidepressant drug treatment of depressive state induced by interferon in patients with active chronic hepatitis: clinical evaluation of efficacy of trazodone hydrochloride. Seishin Igaku (Clinical Psychiatry) 1997, 39(3):291-299.
25. Lang J.P., Meyer N., Doffoel M. Benefits of a preventive psychiatric accompaniment in patients Hepatitis C Virus seropositive (HCV): prospective study concerning 39 patients. Encephale 2003, 29:362-365.
26. Musselman D.L., Lawson D.H., Gumnick J.F., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001, 344:961-966.
27. Morasco B.J., Rifai M.A., Loftis J.M., Indest D.W., Moles J.K., Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007, 103(1-3):83-90.
28. Morasco B.J., Loftis J.M., Indest D.W., et al. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics 2010, 51:401-408.
29. Raison C.L., Woolwine B.J., Demetrashvili M.F., et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007, 25:1163-1174.
30. Diez-Quevedo C., Masnou H., Planas R., et al. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis c: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011, 72(4):522-528.
31. de Knegt R.J., Bezemer G., Van Gool A.R., et al. Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2011, 34:1306-1317.
32. Galvao-de Almeida A., Guindalini C., Batista-Neves S., de Oliveira I.R., Miranda-Scippa A., Quarantini L.C. Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. Gen Hosp Psychiatry 2010, 32:401-405.
33. Cipriani A., Furukawa T.A., Salanti G., et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373:746-758.
34. Cipriani A., Santilli C., Furukawa T.A., et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009, CD006532.
35. Pearlman B.L. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis 2012, 12(9):717-728.
36. Agarwala S.S., O'Day S.J. Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach. Cancer Treat Rev 2011, 37(2):133-142.
37. Capuron L., Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 1999, 340(17):1370.
38. Schaefer M., Schmidt F., Folwaczny C., et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003, 37(2):443-451.
39. Schaefer M., Hinzpeter A., Mohmand A., et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007, 46(4):991-998.
40. Pariante C.M., Orrù M.G., Baita A., Farci M.G., Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999, 354(9173):131-132.
41. Sockalingam S., Abbey S.E., Alosaimi F., Novak M. A review of sleep disturbance in hepatitis C. J Clin Gastroenterol 2010, 44:38-45.
42. Talal A.H., LaFleur J., Hoop R., et al. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther 2013, 37(4):473-481.
43. Fuller B.E., Rodriguez V.L., Linke A., Sikirica M., Dirani R., Hauser P. Prevalence of liver disease in veterans with bipolar disorder or schizophrenia. Gen Hosp Psychiatry 2011, 33(3):232-237.
44. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.